6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
424B3: Prospectus
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer (related to financial reporting)
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
YS BIOPHARMA CO LTD C/WTS 15/03/2028 (TO PUR ORD) | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
YS BIOPHARMA CO LTD C/WTS 15/03/2028 (TO PUR ORD) | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
YS BIOPHARMA CO LTD C/WTS 15/03/2028 (TO PUR ORD) | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
YS BIOPHARMA CO LTD C/WTS 15/03/2028 (TO PUR ORD) | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
YS BIOPHARMA CO LTD C/WTS 15/03/2028 (TO PUR ORD) | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
YS BIOPHARMA CO LTD C/WTS 15/03/2028 (TO PUR ORD) | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
YS BIOPHARMA CO LTD C/WTS 15/03/2028 (TO PUR ORD) | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
YS BIOPHARMA CO LTD C/WTS 15/03/2028 (TO PUR ORD) | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Yi ZHANG(42.6%),All Brilliance Investments Limited(41.9%), etc.
YS BIOPHARMA CO LTD C/WTS 15/03/2028 (TO PUR ORD) | SC 13G: Statement of acquisition of beneficial ownership by individuals-Yi ZHANG(42.6%),All Brilliance Investments Limited(41.9%), etc.
No Data